Drugs / Setidegrasib
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07395024 | Feb → Jul 2026 overdue | — | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05382559 | Jun 2022 → Dec 2028 expected | cancer | Astellas Pharma Inc | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07483983 | Mar 2026 → Sep 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07566052 | Apr 2026 → Jun 2030 expected | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07409272 | Feb 2026 → Aug 2029 expected | pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Setidegrasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07566052 ↗ |
| Known as | ASP3082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483983 ↗ |
| Modality | Other / unclassified | “Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader.” PMID 41879829 ↗ Mar 2026 |
| Route | Intravenous | “Setidegrasib was administered intravenously once weekly at doses of 10 to 800 mg.” PMID 41879829 ↗ Mar 2026 |
| Target | KRAS | “Setidegrasib (ASP3082) is a first-in-class KRAS G12D-targeted protein degrader.” PMID 41879829 ↗ Mar 2026 |